Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

Abstract

EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007.

• Authors: Tomas de Paulis
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 8 Issue 1 Pg. 78-86 (Jan 2007) ISSN: 1472-4472 [Print] England
• PMID: 17263189 (Publication Type: Journal Article, Review)

Chemical References

• Piperazines
• Serotonin 5-HT1 Receptor Agonists
• Sulfonamides
• naluzotan

Topics

• Animals
• Clinical Trials as Topic
• Depressive Disorder, Major (drug therapy)
• Humans
• Molecular Structure
• Piperazines (chemistry, pharmacology, therapeutic use)
• Serotonin 5-HT1 Receptor Agonists
• Smoking Cessation
• Sulfonamides (chemistry, pharmacology, therapeutic use)